Aminoglycoside Plasma Level Measurement in Neonates With Infection

Status Recruiting

Clinical Trial Summary

The aim of this study is to determine whether the plasma concentration of aminoglycoside in Indonesia neonates with infection are within safe and effective range and its association with cochlear toxicity and nephrotoxicity.

Clinical Trial Description

Aminoglycosides are toxic antibiotics, but they are urgently needed to treat newborns with severe infections. Aminoglycosides are well known for their nephrotoxicity and ototoxicity, meanwhile the renal function of the newborns is not yet fully developed.The aminoglycoside dosage currently applied in Indonesia is derived from studies done in Caucasian populations. The safety and efficacy of this dosage regimen, however, have never been evaluated till date. The pharmacokinetic profile of drugs may vary between populations and this may be influenced by genetic factors, lifestyle, drug interactions, etc. The detection of aminoglycoside toxicity in newborns is usually problematic. The present study aims to know the proportion of nephrotoxicity and ototoxicity in newborns in the Cipto Mangunkusumo Hospital treated with gentamicin or amikacin in relation to their trough serum concentration. The serum level of gentamicin and amikacin is assumed to be safe if the trough serum concentrations are < 2 mcg/mL and effective if its is between 5-12 mcg/mL. For amikacin the desired trough serum concentrations are <10 mcg/mL and the peak is between 20-30 mcg/mL. The nephrotoxicity was assessed by measuring the level of kidney injury molecule-1 in urine while the ototoxicity was assessed by Distortion Product Otoacoustic Emission (DPOE) instrument. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01624324
Study type	Observational
Source	Indonesia University
Contact
Status	Recruiting
Phase	N/A
Start date	November 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00477607` - Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin	Phase 2/Phase 3
Completed	`NCT00458887` - Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin	N/A
Recruiting	`NCT03480971` - Treatment of Radiation and Cisplatin Induced Toxicities With Tempol	Phase 2
Completed	`NCT00716976` - Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy	Phase 3
Completed	`NCT01139281` - The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans	Phase 2
Enrolling by invitation	`NCT02819856` - SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity	Phase 2
Terminated	`NCT04226456` - Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity	Phase 4
Recruiting	`NCT05641441` - Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma
Completed	`NCT01263262` - A Comparison of Infection Rates Between Two Surgical Sites	N/A
Not yet recruiting	`NCT01285674` - Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin.	N/A
Not yet recruiting	`NCT01451853` - SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss	Phase 2
Completed	`NCT04262336` - Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment	Phase 1
Not yet recruiting	`NCT00578760` - Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?	N/A
Completed	`NCT00652132` - Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer	Phase 3
Withdrawn	`NCT02382068` - Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin	N/A
Recruiting	`NCT01216800` - Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors	Phase 3
Completed	`NCT01848457` - Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy	Phase 2
Active, not recruiting	`NCT00683319` - Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy	Phase 3